| scholarly article | Q13442814 |
| P50 | author | Jeffrey S. Miller | Q42399944 |
| Dan S Kaufman | Q56332545 | ||
| P2093 | author name string | Valarie McCullar | |
| Melissa A Geller | |||
| David A Knorr | |||
| Laura Bendzick | |||
| Lee Pribyl | |||
| David A Hermanson | |||
| P2860 | cites work | Interleukin-21 activates human natural killer cells and modulates their surface receptor expression | Q24300519 |
| Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells | Q27309991 | ||
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | Q28270998 | ||
| Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer | Q29619483 | ||
| Bioluminescent imaging demonstrates that transplanted human embryonic stem cell-derived CD34(+) cells preferentially develop into endothelial cells | Q33801849 | ||
| Memory-like responses of natural killer cells | Q34007381 | ||
| Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity | Q34016504 | ||
| CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. | Q34310907 | ||
| Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells | Q34600272 | ||
| Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells | Q34605718 | ||
| TGF-β Blockade Controls Ascites by Preventing Abnormalization of Lymphatic Vessels in Orthotopic Human Ovarian Carcinoma Models | Q34694524 | ||
| Relapsed ovarian cancer: challenges and management strategies for a chronic disease | Q34905674 | ||
| Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques | Q35001598 | ||
| NK cells and immune "memory" | Q35539280 | ||
| Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity | Q35909663 | ||
| The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression | Q36652214 | ||
| Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15 | Q36666195 | ||
| Prospects for the use of NK cells in immunotherapy of human cancer. | Q36793616 | ||
| IL-15 trans-presentation promotes human NK cell development and differentiation in vivo | Q37061837 | ||
| Cytokine-induced memory-like natural killer cells | Q37100910 | ||
| A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer | Q37141237 | ||
| Natural killer cell-based immunotherapy in cancer: current insights and future prospects | Q37554765 | ||
| Use of allogeneic NK cells for cancer immunotherapy. | Q37957140 | ||
| Establishment, Characterization, and Successful Adaptive Therapy against Human Tumors of NKG Cell, a New Human NK Cell Line | Q39525496 | ||
| The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer | Q39556474 | ||
| IL-2 Costimulation Enables Statin-Mediated Activation of Human NK Cells, Preferentially through a Mechanism Involving CD56+ Dendritic Cells | Q39643965 | ||
| CD56 negative NK cells: origin, function, and role in chronic viral disease | Q56953283 | ||
| DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells | Q57226771 | ||
| IL-2−driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16− Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion | Q63386780 | ||
| Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer | Q79253356 | ||
| P433 | issue | 10 | |
| P921 | main subject | ovarian cancer | Q172341 |
| xenograft | Q64148587 | ||
| P304 | page(s) | 1297-1306 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | Cytotherapy | Q5201399 |
| P1476 | title | Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model | |
| P478 | volume | 15 |
| Q36916476 | Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells |
| Q94315837 | CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts |
| Q91786100 | Cellular Therapies for the Treatment of Hematological Malignancies; Swine Are an Ideal Preclinical Model |
| Q91115863 | Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells |
| Q90224747 | EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells |
| Q58788761 | Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis |
| Q41812231 | Ex Vivo Expanded Human NK Cells Survive and Proliferate in Humanized Mice with Autologous Human Immune Cells |
| Q47752280 | Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. |
| Q91736879 | Harnessing natural killer cells for the treatment of ovarian cancer |
| Q38714915 | IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer |
| Q36463830 | Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer |
| Q39005211 | Intraperitoneal immunotherapy: historical perspectives and modern therapy |
| Q39239278 | Modeling Natural Killer Cell Targeted Immunotherapies. |
| Q46677873 | Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer |
| Q38941698 | NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival. |
| Q33749684 | OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues |
| Q38857163 | Oxaliplatin regulates expression of stress ligands in ovarian cancer cells and modulates their susceptibility to natural killer cell-mediated cytotoxicity. |
| Q58129516 | PD-L1 blockade enhances anti-tumor efficacy of NK cells |
| Q58582595 | Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients |
| Q35623804 | Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer |
| Q94402935 | SCID pigs: An emerging large animal NK model |
| Q35185573 | Secreted β3-integrin enhances natural killer cell activity against acute myeloid leukemia cells |
| Q47113878 | Sestrin2 and sestrin3 suppress NK-92 cell-mediated cytotoxic activity on ovarian cancer cells through AMPK and mTORC1 signaling |
| Q41337940 | Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice. |
| Q88506528 | Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses |
Search more.